Navigation For Mobile

Category Archives: APIs

Selecting Regulatory Starting Materials: A Q&A With Neuland’s Senior VP of Supply Chain Management

As a follow-up to our recent two-part series on Regulatory Starting Materials Sourcing & Supplier Management, we sat down with Senior Vice President of Supply Chain Management at Neuland Labs…

Posted in APIs, CMC, Neuland Labs, supply chain | Tagged , , , | Comments Off on Selecting Regulatory Starting Materials: A Q&A With Neuland’s Senior VP of Supply Chain Management

Regulatory Starting Materials: How to Source, Analyze and Validate Suppliers (Part II)

In Part I of this two-part series, we explored sourcing and supplier management of Regulatory Starting Materials (RSMs), and how effective designation and justification of RSMs begins with supplier market…

Posted in API synthesis, APIs, supply chain | Tagged , , , | Comments Off on Regulatory Starting Materials: How to Source, Analyze and Validate Suppliers (Part II)

Regulatory Starting Materials: How to Source, Analyze and Validate Suppliers (Part I)

Supply chain management is an essential chapter in the pharmaceutical manufacturing handbook. Managing regulatory starting materials (RSMs) seeks to maximize commercialization and sustainability while meeting and/or exceeding regulatory requirements. Drugmakers…

Posted in API synthesis, APIs, supply chain | Comments Off on Regulatory Starting Materials: How to Source, Analyze and Validate Suppliers (Part I)

Green Generic Drug Substances: Increased Upfront Costs Offset by Long-Term Profitability

Green initiatives may be slowly gaining some traction across the pharmaceutical industry, but there is still a long way to go. These are some astonishing insights from sciencehistory.org. “On a waste-to-product…

Posted in APIs, EHS, generic, green chemistry | Tagged , , | Comments Off on Green Generic Drug Substances: Increased Upfront Costs Offset by Long-Term Profitability

Exploring Neuland’s Therapeutic Segments: Focus on CNS

Drug development is exciting. There’s no getting around it: being a part of an industry which aims to improve human health is a great motivator for waking up and heading…

Posted in APIs, Neuland Labs | Tagged , | Comments Off on Exploring Neuland’s Therapeutic Segments: Focus on CNS

Deuterated Drug Molecules: Perfecting the Gamechanger

Scientific breakthroughs in the pharmaceutical industry can happen overnight, but it still takes time to perfect a discovery’s applications. Deuterium-labeled active pharmaceutical ingredients (APIs) are one specific advancement that has…

Posted in APIs, deuterated molecule, deuteration, deuterium exchange, drugs | Tagged , , | Comments Off on Deuterated Drug Molecules: Perfecting the Gamechanger

Where Does Pharmaceutical Process Control Start?

The idea of gaining – and maintaining – adequate process control during drug synthesis isn’t new. It underscores the entire point of approaches such as Quality by Design (QbD), and…

Posted in API synthesis, APIs, Chemistry, CMC, process chemistry, QbD, Quality, Route Design, Route Scouting | Tagged , , , | Comments Off on Where Does Pharmaceutical Process Control Start?

What Does it Take to Become a Specialist in Late-Phase CMS?

When a drug transitions from early-stage development to late-stage development, the drugmaker has some big decisions to make. Chief among them: Who are they going to work with to move…

Posted in APIs, Capabilities, Chemistry, Contract Manufacturing, process chemistry | Tagged , , , , | Comments Off on What Does it Take to Become a Specialist in Late-Phase CMS?

How CMO Expertise Can Solve Key Challenges in Late Phase Drug API Projects

Stating the obvious here, but drug development is a protracted, expensive and risky process. From the lab bench to pharmacy shelves, bringing a new drug to market often stretches 10+…

Posted in APIs, Capabilities, Chemistry, CMC, Contract Manufacturing, CRO/CMO, drugs, method development, Neuland Labs, outsourcing, process chemistry, Process Engineering, scale-up | Tagged , , , , | Comments Off on How CMO Expertise Can Solve Key Challenges in Late Phase Drug API Projects

How to Create Sustainable Drug Lifecycles with Alternate Route Scouting

Demands on a drug’s synthetic processes naturally evolve during its lifecycle. Scouting alternative methods for synthesizing active pharmaceutical ingredients (APIs) early in process development — before they are needed by changing…

Posted in API synthesis, APIs, atom economy, Chemistry, Effluent, EHS, energy conservation, energy effciency, green chemistry, process chemistry, Route Design, Route Scouting, synthesis, Synthesis Route | Tagged , | Comments Off on How to Create Sustainable Drug Lifecycles with Alternate Route Scouting